Adenoviruses are efficient gene delivery vehicles but have broad native tropism. To this end, finding ways to target this virus specifically to carcinomas has become an important focus of cancer gene therapy. Transductional and transcriptional forms of targeting have been used with promising results in ovarian carcinoma. Therefore, we combined both forms of targeting to investigate the effect on the specificity and efficiency of transgene expression in this disease. We used the tissue-specific SLPI promoter and the ovarian cancer associated targeting adaptor protein, sCARfC6.5. This bispecific protein contains the coxsackie-adenovirus receptor ectodomain and a single-chain antibody specific for c-erbB-2. Viruses containing the SLPI or the ubiquitously expressed CMV promoter, with or without sCARfC6.5, were used for infection of ovarian cancer cell lines, primary ovarian tumor cells, and in an orthotopic model of disseminated ovarian carcinoma. This dual-targeting strategy increased the efficiency and specificity of transgene expression in vitro in reporter and cell-killing assays, and in vivo. By using both the SLPI promoter and sCARfC6.5, transgene expression was increased in ovarian tumors and decreased in normal tissues, including the liver. Thus, we show that combining transcriptional and transductional targeting can increase the efficacy and specificity of adenoviral gene therapy for ovarian carcinoma.
A major determinant for successful cancer gene therapy is the ability to deliver transgene efficiently and specifically to target tumor cells. Adenoviruses (Ads) are efficient gene delivery vehicles but have a broad tropism, resulting from the widespread expression of the coxsackie-adenovirus receptor (CAR), which is the primary receptor for serotypes 2 and 5.
1-3 CAR levels may be highly variable in some carcinomas, including ovarian, causing these tumors to be resistant to Ad infection. 4 Therefore, finding ways to target Ad infection and/or transgene expression to target cancer cells has become an important goal for gene therapy research.
Two primary approaches to adenoviral targeting exist: transductional and transcriptional targeting. 5 Transductional targeting involves the chemical or genetic modification of Ad, redirecting its tropism from CAR to a new target expressed preferentially on the target cell. Transductional targeting not only provides a higher degree of infection specificity, but also a higher degree of infection efficiency. This strategy can be accomplished through the use of targeting adaptor proteins, such as the sCARfC6.5 protein. 6 This bispecific fusion molecule features a trimeric formulation of the secretory form of the CAR ectodomain (responsible for Ad knob binding) fused via a phage T4 fibritin polypeptide to the singlechain antibody (sFv), C6.5, which is specific for the cerbB-2 oncogene. The c-erbB-2 oncogene is upregulated in many ovarian carcinomas. 7, 8 The sCARfC6.5 protein efficiently blocked Ad infection to an even greater extent than a control protein composed of sCAR bound only to fibritin, and redirected the virus to ovarian and breast cancer cell lines expressing c-erbB-2. 6 Transcriptional targeting involves genetically limiting the expression of the introduced gene to specific tissues through the use of tissue-specific promoters (TSPs). Until recently, the most common promoters used to direct expression in the context of Ad gene delivery have been the cytomegalovirus (CMV) immediate early and Rous sarcoma Virus promoters. However, these promoters are ubiquitously active at high levels in a wide range of tissue types. 9 The promoter of the secretory leukoprotease inhibitor (SLPI) gene has recently been described for use as an Ad TSP for ovarian cancer gene therapy. 10 This promoter was able to achieve high levels of transgene expression in ovarian carcinomas that expressed the SLPI gene in vitro and in vivo, while driving lower levels of expression in normal tissues, including the liver. Therefore, the SLPI promoter was able to improve the tumor-to-liver ratio in vivo compared to the CMV promoter. This is of particular importance as the majority of Ad administered intraperitoneally or intravenously localizes to the liver. 11 Since promising results have been obtained employing either of these targeting strategies, we investigated whether combining both forms of targeting could further improve the specificity of transgene expression and the tumor-to-liver ratio in ovarian carcinoma. A previous study reporting on combined targeting has suggested increases in both efficiency and specificity of gene expression in the context of gene delivery to primary pulmonary endothelium.
12 Therefore, we performed in vitro and in vivo experiments comparing a dual-targeted Ad, employing both the SLPI promoter and the sCARfC6.5 targeting adaptor protein, to the respective single-targeted and nontargeted Ads.
In order to measure the effect of combined targeting on gene expression levels in ovarian cancer cell lines, cells were infected with Ads containing the luciferase gene under the control of either the SLPI promoter (Ad.SLPI.- Adenoviral gene delivery to ovarian carcinoma SD Barker et al Luc) or the isogenic control with the CMV promoter (Ad5Luc1), with or without sCARfC6.5. When observing the effect of transcriptional targeting on gene expression, luciferase expression levels with the SLPI promoter alone were between 1 and 40% that of the activity of the CMV promoter ( Figure 1 ). In the positive control cell line for SLPI gene expression, HeLa, 13 gene expression with the SLPI promoter was 11% the expression achieved with the CMV promoter, while in the SLPI negative cell line, OV-4, 14 this percentage was only 0.3%. Gene expression with the SLPI promoter in the ovarian cancer cell lines SKOV3.ip1, OV-3, and Hey was 10, 40, and 2% the levels resulting from infection with Ad5Luc1 only, respectively. In the positive control cell line for c-erbB-2, AU565, 6 gene expression with Ad.SLPI.Luc was 1% the expression achieved with Ad5Luc1, while this same percentage in the c-erbB-2 negative cell line, MDA-MB-468, 6 was 2%. (Figure 1a ). When employing both the CMV promoter and sCARfC6.5, luciferase expression was increased 5-, 60-, 5-, 12, and 85-fold in HeLa, OV-4, SKOV3.ip1, OV-3, and Hey, respectively, compared to Ad5Luc1 alone. A seven-fold increase was observed in AU565 cells (+ control for c-erbB-2), while a two-fold increase was seen in MDA-MB-468 cells (À control for cerbB-2).
Importantly, the dual-targeted Ad.SLPI.Luc achieved expression levels similar to the virus featuring the highly active but unselective CMV promoter. Gene expression with Ad.SLPI.Luc and sCARfC6.5 was 53%, 78%, 147%, and 27% of the expression achieved with the CMV promoter alone in HeLa, SKOV3.ip1, OV-3, and Hey cells, respectively (Figure 1a, d-g ). In fact, no statistical differences existed between cells receiving Ad5Luc1 only and cells receiving Ad.SLPI.Luc plus adaptor protein in SKOV3.ip1, OV3, and Hey cell lines (P¼0.072, 0.223, and 0.098, respectively). Therefore, the transductional targeting was able to correct the reduction of activity caused by the gain in tissue specificity.
Cell lines cultured in vitro may differ from clinical tumors in a variety of ways and may have undergone geno-or phenotypic changes, which can produce results that may not be as clinically relevant. Therefore, we also investigated primary ovarian cancer cells purified from the ascitic fluid of patients diagnosed with ovarian adenocarcinoma 15 ( Figure 2 ). Upon infection of primary ovarian tumor cells with Ad.SLPI.Luc alone, gene expression was 4, 21, and 6% that achieved with Ad5Luc1 alone in patient samples 1, 2, and 3, respectively. Employing Ad.SLPI.Luc and targeting adaptor protein increased expression in these patient samples 3-, 4-, and 11-fold, respectively (P¼0.019, 0.128, and 0.034, respectively, in comparison to Ad.SLPI.Luc alone). When compared to Ad5Luc1 alone, the dual-targeted Ad.SLPI.-Luc achieved 10, 87, and 60% the expression (P¼0.030, 0.784, and 0.185, respectively). Therefore, combining both forms of Ad targeting increases levels of gene expression in both ovarian cancer cell lines and primary ovarian tumor cells isolated from patients.
In order to determine if this increase in gene expression achieved with the dual-targeted approach can translate into greater tumor cell killing, cell lines were infected with viruses containing the Herpes Simplex virus thymidine kinase (HSVtk) gene under the control of either the SLPI promoter (Ad.SLPI.TK) or the CMV promoter (Ad.CMV.TK), with or without targeting adaptor protein (Figure 3) Further, in two of the three ovarian cancer cell lines (SKOV3.ip1 and Hey), cell killing was greater than that accomplished by using Ad.CMV.TK alone. In OV-3 and Hey cells, there was no statistical difference between cell killing with the dual-targeted Ad.SLPI.TK and Ad.CMV.TK alone (P¼0.062 and 0.145, respectively). Based on these data, the correlation between control of transgene expression and cell killing is not understood. These discrepancies are most likely caused in part by the bystander effect, which can be expected to reduce the relative differences between the experimental groups. Further studies may help fully clarify these questions. However, statistical analysis revealed significant im- Adenoviral gene delivery to ovarian carcinoma SD Barker et al provements in tumor cell killing in most ovarian cancer cell lines studied. Further, the goal of this experiment was not complete cell killing and therefore, only a single infection and a modest concentration of GCV were used.
Since it can be concluded that combining both the SLPI promoter and sCARfC6.5 results in increased gene expression in ovarian carcinoma in vitro and because the in vivo system is more complex than its in vitro counterpart, we investigated the effect this dual-targeted Ad would have on the tumor-to-liver ratio in a murine model of ovarian carcinoma. Female SCID mice were injected intraperitoneally with tumor cells. After 10 days, viruses with or without targeting adaptor protein were also injected intraperitoneally. Tissue was harvested and analyzed for luciferase production, as described previously. 11 Gene expression with Ad.SLPI.Luc alone was 90% the expression achieved with Ad5Luc1 alone in the tumor xenografts. However, in the normal organs, this percentage was reduced to 27, 56, 86, 74, 39, and 81% in the liver, lung, spleen, kidney, heart, and peritoneum, respectively.
When investigating the effect of transductional targeting on in vivo gene expression patterns, Ad.SLPI.Luc and sCARfC6.5 increased gene expression in tumor to 30% compared to Ad.SLPI.Luc only (Figure 4) . Importantly, dual targeting decreased gene expression 47, 25, 68, 69, 21, 17, and 23% in the liver, lung, spleen, kidney, heart, peritoneum, and ovary, respectively compared to Ad.-SLPI.Luc alone. Ad5Luc1 and sCARfC6.5 increased gene expression in the tumor to 23% compared to Ad5Luc1 alone. Expression in the normal organs with Ad5Luc1 combined with targeting adaptor protein was decreased when compared to Ad5Luc1 alone, with the exceptions of the lung and heart where expression was increased. Gene expression in the tumor with the dual-targeted Ad.SLPI.Luc was 20% higher than that achieved with Ad5Luc1 alone. However, gene expression with the dualtargeted Ad.SLPI.Luc was decreased 85, 58, 73, 77, 69, and 33% compared to Ad5Luc1 alone in the liver, lung, spleen, kidney, heart, and peritoneum, respectively (P¼0.003, 0.478, 0.039, 0.008, 0.036, and 0.273, respectively, compared to Ad5Luc1 alone). In the tumor xenografts, the expression achieved with the dualtargeted Ad.SLPI.Luc was 97% the expression achieved with Ad5Luc1 and sCARfC6.5, with no statistical difference observed (P¼0.888). However, gene expression with the SLPI promoter and sCARfC6.5 was only 29, 23, 57, 42, 18, and 79% the expression achieved with Ad5Luc1 and targeting adaptor protein in the liver, lung, spleen, kidney, heart, and peritoneum, respectively (P¼0.017, 0.041, 0.035, 0.120, 0.022, and 0.481, respectively, compared to Ad5Luc1 and sCARfC6.5).
The tumor-to-liver ratio with Ad.SLPI.Luc alone was 36:1, but this ratio was increased to 97:1 when utilizing this virus with targeting adaptor protein. Therefore, when employing both transcriptional and transductional forms of targeting, gene expression in ovarian cancer cells is increased, while transduction of normal organs, including the liver, is decreased, thereby further improving the tumor-to-liver ratio in this stringent model of ovarian carcinoma. In the proof-of-concept experiments described in this paper, these differences were not statistically significant with the statistical methods used, which could reflect aspects such as sample size and individual variation associated with in vivo conditions. Nevertheless, if these results can be confirmed in further studies, they could be important because of adenovirus' propensity to localize to the liver with potential for subsequent hepatotoxicity, which has been demonstrated in humans 16 and mice, even with the relative compartmentalization provided by intraperitoneal delivery. 11 It can be speculated that in addition to decreasing potential liver toxicity, a selective decrease in liver expression might enable an increase in the amount of virus administered for intraperitoneal treatment.
Employment of sCARfC6.5 increased the tumor-toliver ratio 269% compared to the SLPI promoter alone and was able to achieve higher gene expression than Ad5Luc1 alone and equal expression compared to Ad5Luc1 and sCARfC6.5. Thus, adding transductional targeting to Ad gene delivery in vivo was able to increase tissue-specific expression with the SLPI promoter to higher levels than could be achieved with the CMV promoter. Also, the data suggested that it may be feasible to gain specificity with regard to gene transfer to other organs, such as the spleen and kidney (Figure 4) .
Most published clinical trials to date have employed Ads containing nonspecific promoters such as the CMV promoter. The CMV promoter has been widely used because of its extremely high activity. Consequently, most TSPs that have been investigated for the purposes of reducing expression in nontarget organs unfortunately also demonstrate lower activity in target tissues. 17, 18 Therefore, an important finding in this study was that it was possible to reconstitute gene delivery ( Figure 1 ) and cell killing (Figure 3) to the level obtained with the CMV promoter, while further decreasing transgene expression in normal tissues. Remarkably, the same was true in primary ovarian cancer cells purified from patient ascites ( Figure 2) and in an orthotopic model of disseminated ovarian cancer (Figure 4 ).
In conclusion, we have demonstrated that by combining two complementary forms of Ad targeting, an increase in both efficiency and specificity of gene expression can be achieved. Before these techniques can be utilized safely and effectively, patients must be screened for specific genes, which are upregulated in tumor versus normal tissues. Upon these considerations, this method of targeting has many potential advantages, including the availability of various transductional targeting modalities. Further, because of developments in gene expression analysis, such as microarrays, many new molecular targets are being discovered. Also, a dualtargeting strategy might be useful for oncolytic viruses for an improvement in the specificity of viral replication, if the targeting moiety can be incorporated into the virus genome and rendered compatible with virus replication. Ultimately, advances such as those described here may translate into improved safety and efficacy in the treatment of ovarian cancer patients with disease refractory to currently available modalities.
